Telenursing in care education for caregivers of psoriasis patients: a protocol for a randomized controlled trial

远程护理在银屑病患者照护者护理教育中的应用:一项随机对照试验方案

阅读:1

Abstract

BACKGROUND: Psoriasis is a chronic inflammatory skin disorder that imposes significant physical, psychological, and social burdens on patients and their family caregivers. Family caregivers play a crucial role in patient care, but often experience substantial caregiving burden and psychological distress. Telenursing, as an emerging approach in healthcare, offers an accessible and cost-effective method for providing education and support to caregivers. This study aims to evaluate the effectiveness of telenursing in care education for family caregivers of patients with psoriasis. METHODS: A single-site, open-label randomized clinical trial with two parallel groups (intervention and control) will be conducted at the dermatology clinic of Razi Hospital, Tehran University of Medical Sciences, between June 2025 and November 2025. Seventy family caregivers of patients with psoriasis who meet the inclusion criteria will be recruited and randomly assigned (38 per group) to either a telenursing-based care education program (intervention) or usual education (control). The intervention will last six weeks, including four weeks of structured online education via WhatsApp and Skyroom, followed by two weeks of follow-up. Primary outcomes (psychological well-being and caregiving burden) and the secondary outcome (caregiver self-efficacy) will be assessed at baseline and post-intervention using validated questionnaires. Statistical analyses will be conducted using SPSS software V.23, with a significance level of p < 0.05. DISCUSSION AND CONCLUSION: This trial will evaluate whether a structured telenursing program can improve psychological well-being and caregiver self-efficacy while reducing caregiving burden among family caregivers of patients with psoriasis. The findings may inform scalable nurse-led telehealth strategies to support caregivers in chronic dermatological conditions. Trial registration IRCT20240319061338N2, registered on 17 January 2025 in the Iranian Registry of Clinical Trials (IRCT) ( http://www.irct.ir/ ).

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。